ERBB2 and cancer: Although endocrine (for ER+ tumours), cytotoxic chemotherapy (for ER- tumours) or Herceptin (for HER2+ tumours) regimens are successful treatments for some breast cancer patients, mortality due to recurrence of cancers which develop drug resistance and metastases is still common [43].